Moderna Fact Sheet for Recipients and Caregivers .
Pfizer-Biontech Fact Sheet for Recipients and Caregivers .
COVID-19 is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not
been seen before. You can get COVID-19 through contact with another person who has the
virus. It is predominantly a respiratory illness that can affect other organs.
People with COVID19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness.
Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or
chills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or
smell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.
The protection someone gains from having an infection (called “natural immunity”) varies depending on the disease, and it varies from person to person.
Because this virus is new, we don’t know how long natural immunity might last. Current evidence suggests that getting the virus again
(reinfection) is uncommon in the 90 days after the first infection with the virus that causes COVID-19.
We won’t know how long immunity lasts after vaccination until we have more data on how well COVID-19 vaccines work in real-world conditions.
Experts are working to learn more about both natural immunity and vaccine-induced immunity. CDC will keep the public informed as new evidence becomes available.
The Moderna COVID-19 Vaccine contains the following ingredients: messenger ribonucleic acid
(mRNA), lipids (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG],
cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine,
tromethamine hydrochloride, acetic acid, sodium acetate, and sucrose.
The Pfizer-BioNTech COVID-19 Vaccine includes the following ingredients: mRNA,
lipids ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2
[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-Distearoyl-sn-glycero-3-
phosphocholine, and cholesterol), potassium chloride, monobasic potassium
phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose.
People who are pregnant and part of a group recommended to receive the COVID-19 vaccine may choose to be vaccinated.
If you have questions about getting vaccinated, talking with a healthcare provider may might help you make an informed decision.
While breastfeeding is an important consideration, it is rarely a safety concern with vaccines.
No data are available yet on the safety of COVID-19 vaccines in lactating women or on the effects of mRNA vaccines on breastfed infants
or on milk production/excretion. mRNA vaccines are not thought to be a risk to breastfeeding infants. People who are breastfeeding
and are part of a group recommended to receive a COVID-19 vaccine, such as healthcare personnel, may choose to be vaccinated.
To make sure that more information is gathered regarding the safety of these vaccines when administered during pregnancy, pregnant
people are encouraged to enroll in v-safe, CDC’s new smartphone-based tool being used to check-in on people’s health after they receive a
COVID-19 vaccine. If pregnant people report health events through v-safe after vaccination, someone from CDC may call to check on them and
get more information. Additionally, pregnant people enrolled in v-safe will be contacted by CDC and asked to participate in a pregnancy
registry that will monitor them through pregnancy and the first 3 months of infancy. Learn more about COVID-19 vaccination
considerations for people who are pregnant or breastfeeding.
People with underlying medical conditions can receive the FDA-authorized COVID-19 vaccines provided they have not had an immediate or
severe allergic reaction to a COVID-19 vaccine or to any of the ingredients in the vaccine. Learn more about vaccination
considerations for persons with underlying medical conditions.
Vaccination is an important consideration for adults of any age with certain underlying
medical conditions because they are at increased risk for severe illness from the virus that causes COVID-19.
Serious problems from vaccination can happen, but they are rare. CDC has learned of reports that some people have experienced
severe allergic reactions—also known as anaphylaxis—after getting a COVID-19 vaccine. As an example, an allergic reaction is
considered severe when a person needs to be treated with epinephrine or EpiPen© or if they must go to the hospital.
Learn more about COVID-19 vaccines and allergies.
If you get a COVID-19 vaccine and you think you might be having a severe allergic reaction after leaving the vaccination site, seek immediate medical care by calling 911.
You can report side effects and reactions using either v-safe or the Vaccine Adverse Event Reporting System (VAERS.)
Healthcare providers will be required to report certain adverse events following vaccination to VAERS. Healthcare providers also have to adhere to any revised safety reporting requirements according to FDA’s conditions of authorized use throughout the duration of any Emergency Use Authorization; these requirements would be posted on FDA’s websiteexternal icon
You can expect normal side effects after you are vaccinated. Refer to
What to Expect at Your Appointment to Get Vaccinated for COVID-19.
for additional information.
You are not eligibile for the COVID-19 vaccine if you meet any of the following conditions:
Severe allergic reaction (e.g., anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine or any of its components
Immediate allergic reaction of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components (including polyethylene glycol [PEG])*
Immediate allergic reaction of any severity to polysorbate (due to potential cross-reactive hypersensitivity with the vaccine ingredient PEG)*
Acute moderate to severe illness at time of vaccination
Received any vaccine within the past 14 days
Received treatment for COVID-19 with monoclonal antibodies or convalescent plasma within the past 90 days
Have tested positive for COVID-19 within the past 30 days
Currently in quarantine for COVID-19 exposure
Yes. Due to the severe health risks associated with COVID-19 and the fact that reinfection with COVID-19 is possible, you should be vaccinated
regardless of whether you already had COVID-19 infection. If you were treated for COVID-19 symptoms with monoclonal antibodies or convalescent
plasma, you should wait 90 days before getting a COVID-19 vaccine. Talk to your doctor if you are unsure what treatments you received or if
you have more questions about getting a COVID-19 vaccine.
Experts do not yet know how long someone is protected from getting sick again after recovering from COVID-19.
The immunity someone gains from having an infection, called “natural immunity,” varies from person to person. It is rare for someone who has
had COVID-19 to get infected again. It also is uncommon for people who do get COVID-19 again to get it within 90 days of when they recovered from
their first infection. We won’t know how long immunity produced by vaccination lasts until we have more data on how well the vaccines work.
Both natural immunity and vaccine-induced immunity are important aspects of COVID-19 that experts are working to learn more about, and
CDC will keep the public informed as new evidence becomes available.
Yes. Not enough information is currently available to say if or when CDC will stop recommending that people wear masks and avoid close contact
with others to help prevent the spread of the virus that causes COVID-19.
Experts need to understand more about the protection that COVID-19 vaccines provide in real-world conditions before making that decision.
Other factors, including how many people get vaccinated and how the virus is spreading in communities, will also affect this decision.
We also don’t yet know whether getting a COVID-19 vaccine will prevent you from spreading the virus that causes COVID-19 to other people,
even if you don’t get sick yourself. CDC will continue to update this page as we learn more.
To protect yourself and others, follow these recommendations:
Together, COVID-19 vaccination and following CDC’s recommendations for how to protect yourself and others will offer the best protection
from getting and spreading COVID-19.
Moderna doses should be given 1 month (28 days) apart
The Pfizer-BioNTech doses should be given 3 weeks (21 days) apart.
You should get your second shot as close to the recommended as possible. However, there is no maximum
interval between the first and second doses for either vaccine. You should not get the second dose earlier than the recommended interval.
The Moderna COVID-19 Vaccine will be given to you as an injection into the muscle.
The Moderna COVID-19 Vaccine vaccination series is 2 doses given 1 month apart.
If you receive one dose of the Moderna COVID-19 Vaccine, you should receive a second dose of
the same vaccine 1 month later to complete the vaccination series.
The Pfizer-BioNTech COVID-19 Vaccine will be given to you as an injection into the muscle.
The Pfizer-BioNTech COVID-19 Vaccine vaccination series is 2 doses given 3 weeks apart.
If you receive one dose of the Pfizer-BioNTech COVID-19 Vaccine, you should receive
a second dose of this same vaccine 3 weeks later to complete the vaccination series.
Wait at least 14 days before getting any other vaccine, including a flu or shingles vaccine,
if you get your COVID-19 vaccine first. And if you get another vaccine first, wait at least 14 days before getting your COVID-19 vaccine.
If a COVID-19 vaccine is inadvertently given within 14 days of another vaccine, you do not need to restart the
COVID-19 vaccine series; you should still complete the series on schedule. When more data are available on the safety
and effectiveness of COVID-19 vaccines administered simultaneously with other vaccines, CDC may update this recommendation.
For the most updated information please visit
What to Expect after Getting a COVID-19 Vaccine
On the arm where you received the shot:
Throughout the rest of your body:
If you have pain or discomfort, talk to your doctor about taking an over-the-counter medicine, such as ibuprofen or acetaminophen.
To reduce pain and discomfort where you received the shot:
To reduce discomfort from fever:
In most cases, discomfort from fever or pain is normal. Contact your doctor or healthcare provider:
The vaccination provider may include your vaccination information in your state/local
jurisdiction’s Immunization Information System (IIS) or other designated system. This will
ensure that you receive the same vaccine when you return for the second dose. For more
information about IISs, click
The Emergency Use Authorization (EUA) authority allows FDA to help strengthen the nation’s public health protections
against CBRN threats by facilitating the availability and use of MCMs needed during public health emergencies.
Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved
medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or
prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate,
approved, and available alternatives.
Section 564 of the FD&C Act was amended by the Project Bioshield Act of 2004 and was further amended by
the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), the 21st Century Cures Act of 2016,
and Public Law 115-92 of 2017.
Please note: a determination under section 319 of the Public Health Service
Act that a public health emergency exists, such as the one issued on January 31, 2020,
does not enable FDA to issue EUAs. A separate determination and declaration are needed
under section 564 of the Federal Food, Drug and Cosmetic Act to enable FDA to issue EUAs, provided other statutory criteria are met.
For More information on Emergency User Authorization
Any eligible member can pre-register online.
When vaccine is available, those who qualify under Alabama Department of Public Health (ADPH) guidelines will be notified to schedule an appointment.
**Please note that eligibility does not guarantee an appointment will be available to you. Appointment availability is solely dependent on vaccine supply.
Pre-registration allows any eligible member to register their contact information with the State Employees' Insurance Board (SEIB) and indicate that they would like to be notified when the vaccine is available to them.
After you enter your information, if you’re eligible to receive the vaccine, you will receive an email with instructions on how to schedule your appointment.
No, registering will not change when you receive your vaccine.
However, registering and providing your contact information will make it easier for the State Employees' Insurance Board (SEIB) to notify you when it is your turn.
Unfortunately, if you miss your appointment you will have to reschedule and book another appointment at the next available time slot.
As these time slots are high in demand, please remember to mark your calendars and set reminders in order to avoid missing appointments.
The COVID-19 vaccines currently in use require a second dose. You need both doses in order for the vaccine to work correctly.
You will be scheduled for your second appointment during the check-out process after receiving your first dose.